Ionis, Royalty in $1.1B Deal to Advance Ionis’ Genetic Medicines, Commercial Readiness

 

• Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsen

• Royalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestones

• Agreement enables Ionis to achieve commercial readiness for multiple late-stage programs and advance its innovative pipeline of genetic medicines

https://finance.yahoo.com/news/royalty-pharma-ionis-enter-royalty-141500753.html